Malapure, Sumeet Suresh (2020) Radioiodine therapy of graves’ disease and the uptake paradox. Indian Journal of Nuclear Medicine, 35 (1). pp. 17-20. ISSN 0972-3919

PDF 00012953.pdf - Published Version Restricted to Registered users only Download (748kB) | Request a copy

Abstract

Purpose of the Study: Radioiodine (131I) therapy is approved and well‑accepted modality for the treatment of hyperthyroidism. The dosage of 131I for successful treatment is based on many factors; however, an objective tool to determine the dose was missing. In a retrospective study, we found that high 131I uptake values required more dose to achieve desirable results contrary to the belief. Materials and Methods: Clinically and scintigraphically proven Graves’ disease patients with high 131I uptake (>50%) were accrued for this study and block randomized into low‑dose (Group I) and high‑dose (Group II) groups. Low activity (5 mCi) was administered in Group I and higher activity (10 mCi) in Group II. The patients were followed up after 3 months with thyroid function tests to determine the outcome. Results: A total of 344 patients were analyzed at the end of 3 months, with 174 in low‑dose group and 170 in high‑dose group. Euthyroidism/hypothyroidism was achieved in significantly higher number of patients as compared to the low‑dose group. Conclusion: The higher dose of 131I is required to achieve euthyroidism/hypothyroidism in patients with high 131I uptake.

Actions (login required)

View Item